Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study
NCT ID: NCT04397432
Last Updated: 2023-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
878 participants
OBSERVATIONAL
2020-08-28
2026-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is a real-world study and the case records of patients with advanced non-small cell lung cancer who visited the research centers from January 2014 to December 2017 and met the inclusion criteria will be collected. Medical data including patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, and so on will be extracted to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elemene plus TKIs
This is a real-world study, we just record the patient's medication who used Elemene Injectable Emulsion and/or Elemene Oral Emulsion plus TKIs. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
No interventions assigned to this group
TKIs only
This is a real-world study, we just record the patient's medication who used TKIs only. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with EGFR mutation.
3. Received EGFR-TKIs at least once.
4. Received Elemene Injectable Emulsion and/or Elemene Oral Emulsion at least once ( only for Elemene plus TKIs group).
5. Completeness of important outcome measures and medical records related to the study.
Exclusion Criteria
2. The researchers did not consider it appropriate to participate in this study for other reasons.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LinkDoc Technology (Beijing) Co. Ltd.
INDUSTRY
Tian Xie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tian Xie
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ziping Wang, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Cancer Hospital & Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Panjin Central Hospital
Panjin, Liaoning, China
Shenyang Tenth People's Hospital
Shenyang, Liaoning, China
The Second People's Hospital of Yangcheng County
Jincheng, Shanxi, China
Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Hangzhou Cancer Hospital
Hangzhou, Zhejiang, China
Tongde Hospital of Zhejiang Province
Hangzhou, Zhejiang, China
Zhejiang Hospital
Hangzhou, Zhejiang, China
Zhejiang Xiaoshan Hospital
Hangzhou, Zhejiang, China
Hangzhouwan Hospital
Ningbo, Zhejiang, China
Dongfang Hospital Beijing University of Chinese Medicine
Beijing, , China
Beijing Cancer Hospital
Beijing, , China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, , China
Cancer Hospital of Huanxing Chaoyang District Beijing
Beijing, , China
Chongqing University Cancer Hospital
Chongqing, , China
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai, , China
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai, , China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Tianjin, , China
Tianjin Medical University General Hospital
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HangzhouNU
Identifier Type: -
Identifier Source: org_study_id